ArticleJournal of experimental & clinical cancer research : CR2024

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.

Sara Santana-Hernández et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.